Introducing Hamlet BioPharma to investors
Hamlet BioPharma the innovative pharmaceutical company with a strong portfolio of projects for the treatment of cancer and infections today launches the new website introducing Hamlet BioPharma, providing a first overview of the company, recent transactions and the main projects. A merger of HAMLET Pharma and SelectImmune Pharma was formally decided on May 17[th], 2023. The decisions were taken by extra general assemblies in the respective companies. The transaction also includes the acquisition of a tuberculosis project and a collaboration agreement with Linnane Pharma. The formal